Loading…
Employees: 635
Size Zota Health Care (ZOTA.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $395M, the 946th largest of 1,058 India companies the cockpit tracks. Shares closed at ₹1,231 on 6 Nov 2026.
Performance Over six months the shares fell 5.7%, against -16.1% for the median peer and 0.0% for the India market (cap-weighted) — 7th highest of 21 in its peer set.
Growth Revenue grew 69.0% over the last twelve months (peer median +7.9%); the operating margin is -15.6% (peer median -12.4%).
Valuation It trades at 5.8× enterprise value to sales against a peer median of 5.5× (9th cheapest of 17).
Capital Return on invested capital runs 20.3 points below its cost of capital (10.6% WACC).
Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹6.79B | ₹5.39B | ₹2.92B | ₹1.80B | ₹1.39B |
| Revenue growth | — | +84% | +62% | +29% | — |
| Gross profit | ₹733M | ₹605M | ₹221M | ₹310M | ₹305M |
| EBITDA | -₹2.75M | ₹186M | -₹49.7M | ₹76.7M | ₹74.9M |
| Net income | -₹1.13B | -₹739M | -₹564M | -₹143M | -₹57.7M |
| Free cash flow | n/a | -₹2.05B | -₹949M | -₹218M | -₹137M |
| Capital expenditure | n/a | ₹1.26B | ₹460M | ₹167M | ₹125M |
| Total debt | ₹2.71B | ₹2.70B | ₹1.40B | ₹953M | ₹451M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ZOTA.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.3% | -11.3% | 9th highest of 21 |
| 6-month return | -5.7% | -16.1% | 7th highest of 21 |
| Distance from 52-week high | -29.2% | -41.4% | 7th highest of 21 |
| Revenue growth (TTM) | +69.0% | +7.9% | 5th highest of 17 |
| Operating margin | -15.6% | -12.4% | 6th lowest of 17 |
| EV / Sales | 5.8× | 5.5× | 9th cheapest of 17 |
| ROIC minus cost of capital | -20.3 pp | -7.5 pp | 3rd lowest of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zota Health Care ZOTA.NS | India | $395M | -6% | +69% | -16% | 5.8× | n/a | n/a |
| SanBio 4592.T | Japan | $393M | -58% | n/a | n/a | n/a | n/a | n/a |
| Heartseed 219A.T | Japan | $393M | +52% | +197% | 9% | 21.4× | 50.0% | +73.2% |
| Tiansheng Pharmaceutical 002872.SZ | China | $392M | +15% | -1% | -13% | 5.2× | 23.2% | -15.7% |
| Tuoxin Pharmaceutical 301089.SZ | China | $400M | -22% | +17% | -20% | 5.8× | n/a | n/a |
| Kwality Pharmaceuticals KPL.NS | India | $401M | +111% | +38% | 21% | 6.8× | n/a | n/a |
| Hyundai Bioscience 048410.KS | South Korea | $401M | -58% | +78% | -580% | 158.2× | n/a | n/a |
| Guangdong Lifestrong Pharmacy 301111.SZ | China | $401M | -16% | +7% | -2% | 7.9× | n/a | n/a |
| JW Pharmaceutical 001060.KS | South Korea | $402M | -28% | +10% | 14% | 0.7× | -16.9% | +7.2% |
| Shandong Sinobioway Biomedicine 002581.SZ | China | $404M | -40% | +91% | -65% | 7.8× | n/a | n/a |
| iX Biopharma 42C.SI | Singapore | $386M | +10% | -12% | -140% | 70.7× | n/a | n/a |
| MapLight Therapeutics MPLT | United States | $385M | -75% | n/a | n/a | n/a | n/a | n/a |
| JCR Pharmaceuticals 4552.T | Japan | $383M | -11% | +3% | -14% | 2.9× | n/a | n/a |
| Hansa Biopharma HNSA.ST | Sweden | $410M | +39% | -4% | -304% | 23.7× | n/a | n/a |
| Shaanxi Panlong Pharmaceutical 002864.SZ | China | $411M | -13% | -9% | 9% | 1.6× | -0.4% | +11.2% |
| Anhui Sunhere Pharmaceutical Excipients 300452.SZ | China | $412M | -16% | +9% | 19% | 2.4× | -4.5% | +12.1% |
| Jiangxi Synergy Pharmaceutical 300636.SZ | China | $414M | -16% | -2% | 3% | 3.5× | n/a | n/a |
| Guizhou Yibai Pharmaceutical 600594.SS | China | $376M | -21% | -26% | -15% | 2.0× | 9.0% | -11.3% |
| Assembly Biosciences ASMB | United States | $416M | -31% | +125% | -12% | 1.3× | n/a | n/a |
| Relmada Therapeutics RLMD | United States | $416M | -47% | n/a | n/a | n/a | n/a | n/a |
| Rezolute RZLT | United States | $375M | +21% | n/a | n/a | n/a | n/a | n/a |